The Potential of Positron-Emission Tomography for Pharmacokinetic and Pharmacodynamic Studies of Neuroleptics
The antipsychotic effect of neuroleptic drugs is well established (Delay and Deniker 1957; Klein and Davis 1962). The individual response to treatment with neuroleptic drugs is, however, highly variable. Some patients do not respond to treatment, and in some patients severe side effects are recorded. For such reasons there is a need for useful methods to examine the mechanism of antipsychotic drug action in patients and for measures to guide the determination of proper dosage. During the past 20 years techniques have been available for the measurement of drug concentrations in body fluids. Despite a large number of studies on the relationships between serum drug concentrations and antipsychotic effect, no consistent relationships have been generally confirmed (Dahl 1986).
KeywordsDopamine Schizophrenia Haloperidol Clozapine Chlorpromazine
Unable to display preview. Download preview PDF.
- Farde L, Wiesel F-A, Ehrin E, Hall H, Sedvall G (1986a) Quantitative PET-scan determination of dopamine-D2 receptor binding in schizophrenic patients treated with distinct classes of antipsychotic drugs. In: Shagass C, et al. (eds) World Congress of Biological Psychiatry, 8–13 September 1985. Elsevier, New York, pp 363–365 (Developments in psychiatry, vol 7 )Google Scholar
- Farde L, Wiesel F-A, Halldin H, Sedvall G (1988 a) Central D2-dopamine receptor occupancy in schizophrenic patients treated with antipsychotic drugs. Arch Gen Psychiatry 45: 71–76Google Scholar
- Jorgensen A (1986) Metabolism and pharmacokinetics of antipsychotic drugs. In: Bridges JW, Chasseaud LF (eds) Progress in drug metabolism, vol 9. Taylor and Francis, London, pp 111–174Google Scholar
- Klein D, Davis J (1962) Diagnosis and drug treatment of psychiatric disorders. Williams and Williams, BaltimoreGoogle Scholar
- Smith M, Wolf AD, Brodie JD, Arnett CD, Barouche F, Shine C-Y, Fowler JS, Russell JAG, MacGregor RR, Wolkin A, Angrist B, Rotrosen J, Peselow E (1988) Serial [18F]N-Methylspiroperidol PET studies to measure changes in anti-psychotic drug D-2 receptor occupancy in schizophrenic patients. Biol Psychiatry 23: 653–663PubMedCrossRefGoogle Scholar